Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : SRPT save search
Hansa Biopharma Expects Strong First Quarter 2024 Sales Performance
Published: 2024-04-02 (Crawled : 06:00) - prnewswire.com
SRPT | $115.53 -0.88% -0.9% 640K
|
Health Technology
|
| O: -0.15%
H: 0.88%
C: -0.53%
sales first biopharma
Sarepta Therapeutics to Present at Upcoming Investor Conferences - March 4, 2024
Published: 2024-03-04 (Crawled : 14:00) - biospace.com/
SRPT | $115.53 -0.88% -0.9% 640K
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: -3.72%
therapeutics
Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Recent Corporate Developments
Published: 2024-02-28 (Crawled : 00:00) - biospace.com/
SRPT | $115.53 -0.88% -0.9% 640K
|
Health Technology
|
| O: -0.28%
H: 1.03%
C: -2.58%
therapeutics financial results
Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2023 Financial Results
Published: 2024-02-21 (Crawled : 15:30) - biospace.com/
SRPT | $115.53 -0.88% -0.9% 640K
|
Health Technology
|
| O: -0.97%
H: 1.06%
C: -1.88%
therapeutics financial results
Sarepta Therapeutics Announces U.S. FDA Acceptance of an Efficacy Supplement to Expand the ELEVIDYS Indication
Published: 2024-02-16 (Crawled : 15:00) - biospace.com/
SRPT | $115.53 -0.88% -0.9% 640K
|
Health Technology
|
| O: 12.15%
H: 2.1%
C: -3.89%
fda therapeutics
Global Cell Penetrating Peptide Market Forecast Report to 2030, Featuring Biosynth, Creative Peptides, Cupid Peptide, Alta Bioscience, AnaSpec, Peptomyc, PolyPeptide, Bachem & Sarepta Therapeutics
Published: 2024-02-05 (Crawled : 11:00) - prnewswire.com
SRPT | $115.53 -0.88% -0.9% 640K
|
Health Technology
|
| O: 0.12%
H: 3.45%
C: 3.4%
RVNC | $3.77 -0.53% -0.53% 1.6M
|
Health Technology
|
| O: -2.42%
H: 1.05%
C: -2.67%
report cell global therapeutics market
Sarepta Therapeutics Announces Positive Data from Part B of MOMENTUM, a Phase 2 Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51
Published: 2024-01-29 (Crawled : 15:30) - biospace.com/
SRPT | $115.53 -0.88% -0.9% 640K
|
Health Technology
|
| O: 0.06%
H: 3.66%
C: 1.43%
srp-5051 positive therapeutics duchenne study
Regenerative Medicine Market Worth $49.0 Billion | MarketsandMarkets™.
Published: 2024-01-26 (Crawled : 15:30) - prnewswire.com
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: -0.27%
H: 0.38%
C: 0.07%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 0.29%
H: 0.15%
C: -0.13%
SRPT | $115.53 -0.88% -0.9% 640K
|
Health Technology
|
| O: 0.69%
H: 0.12%
C: -1.75%
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: 0.0%
H: 0.35%
C: -0.88%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: 0.1%
H: 0.47%
C: 0.39%
market
Sarepta Therapeutics Initiates Screening in EMERGENE, a Phase 3 Clinical Study of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4
Published: 2024-01-16 (Crawled : 23:00) - biospace.com/
SRPT | $115.53 -0.88% -0.9% 640K
|
Health Technology
|
| O: -1.19%
H: 1.04%
C: -0.02%
srp-9003 treatment therapeutics study
REGENXBIO Announces Positive Interim Data from Phase II AAVIATE® Trial of ABBV-RGX-314 for the Treatment of Wet AMD Using Suprachoroidal Delivery
Published: 2024-01-16 (Crawled : 20:00) - prnewswire.com
SRPT | $115.53 -0.88% -0.9% 640K
|
Health Technology
|
| O: -0.49%
H: 3.17%
C: 1.94%
RGNX | $15.67 -2.73% -2.87% 570K
|
Health Technology
|
| O: -0.13%
H: 0.0%
C: -7.15%
CLSD P | $1.29 -2.27% -2.33% 230K
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: -6.94%
rgx-314 aaviate positive treatment trial
REGENXBIO Announces Presentation at the Hawaiian Eye and Retina 2024 Meeting
Published: 2024-01-10 (Crawled : 12:00) - prnewswire.com
SRPT | $115.53 -0.88% -0.9% 640K
|
Health Technology
|
| O: 1.79%
H: 0.0%
C: -2.23%
RGNX | $15.67 -2.73% -2.87% 570K
|
Health Technology
|
| O: -0.48%
H: 2.74%
C: 1.85%
presentation retina meeting eye
Sarepta Therapeutics Reports Preliminary* Fourth Quarter and Full-Year 2023 Net Product Revenue
Published: 2024-01-08 (Crawled : 00:00) - biospace.com/
SRPT | $115.53 -0.88% -0.9% 640K
|
Health Technology
|
| O: -0.2%
H: 5.95%
C: 5.62%
revenue therapeutics
U.S. District Court Issues Decision on REGENXBIO and University of Pennsylvania NAV® Technology Patent Infringement Lawsuit
Published: 2024-01-08 (Crawled : 12:00) - prnewswire.com
SRPT | $115.53 -0.88% -0.9% 640K
|
Health Technology
|
| O: -0.2%
H: 5.95%
C: 5.62%
RGNX | $15.67 -2.73% -2.87% 570K
|
Health Technology
|
| O: -2.55%
H: 0.0%
C: -9.92%
nav patent technology
Sarepta Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Published: 2024-01-02 (Crawled : 20:00) - biospace.com/
SRPT | $115.53 -0.88% -0.9% 640K
|
Health Technology
|
| O: -0.96%
H: 1.88%
C: 0.74%
conference therapeutics
Sarepta Therapeutics Submits Efficacy Supplement to Expand the ELEVIDYS Label to include Duchenne Muscular Dystrophy Patients without Restriction to Age or Ambulatory Status
Published: 2023-12-22 (Crawled : 20:00) - biospace.com/
SRPT | $115.53 -0.88% -0.9% 640K
|
Health Technology
|
| O: 1.37%
H: 3.21%
C: 2.77%
label therapeutics duchenne
Emerging Market Trends in Muscular Dystrophy: A DelveInsight Analysis of Becker Muscular Dystrophy, Myotonic Dystrophy, Facioscapulohumeral Muscular Dystrophy, and Limb-girdle Muscular Dystrophy
Published: 2023-11-06 (Crawled : 22:00) - prnewswire.com
SRPT | $115.53 -0.88% -0.9% 640K
|
Health Technology
|
| O: 0.65%
H: 4.43%
C: 2.87%
RNA | $22.74 -1.3% -1.32% 1M
|
Health Technology
|
| O: -0.57%
H: 10.72%
C: 10.63%
trends market
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Enviva Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - EVA
Published: 2023-11-06 (Crawled : 01:00) - prnewswire.com
DLO | $14.52 -4.47% -4.68% 1.2M
|
Information
|
| O: 1.14%
H: 0.81%
C: -2.1%
EVA | $0.3551 -10.1% 0.11% 850K
|
Process Industries
|
| O: 1.3%
H: 0.04%
C: -6.85%
SRPT | $115.53 -0.88% -0.9% 640K
|
Health Technology
|
| O: 4.47%
H: 1.98%
C: -1.72%
trusted deadline
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages DLocal Limited Investors to Secure Counsel Before Important Deadline in Securities Class Action - DLO
Published: 2023-11-05 (Crawled : 00:00) - prnewswire.com
DLO | $14.52 -4.47% -4.68% 1.2M
|
Information
|
| O: 1.14%
H: 0.81%
C: -2.1%
AAP | $78.69 1.93% 0.0% 1.7M
|
Retail Trade
|
| O: 5.2%
H: 1.96%
C: -0.7%
SRPT | $115.53 -0.88% -0.9% 640K
|
Health Technology
|
| O: 4.47%
H: 1.98%
C: -1.72%
deadline
Sarepta Therapeutics to Present at the UBS Biopharma Conference
Published: 2023-11-02 (Crawled : 15:00) - biospace.com/
SRPT | $115.53 -0.88% -0.9% 640K
|
Health Technology
|
| O: 3.8%
H: 3.51%
C: -2.1%
conference biopharma therapeutics
Nicklaus Children's Hospital Now Administering the First FDA-Approved Gene Therapy for Duchenne Muscular Dystrophy
Published: 2023-11-01 (Crawled : 20:00) - biospace.com/
SRPT | $115.53 -0.88% -0.9% 640K
|
Health Technology
|
| O: 1.62%
H: 12.24%
C: 11.87%
hospital duchenne therapy
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.